21 December 2021 | News
Next-generation facility will support growth of startups and accelerate early-stage innovation with state-of-the-art research infrastructure, scientific and business support
image credit- twitter
BeiGene has announced the official launch of the BeiGene Bioisland Innovation Centre (BIC) in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations. The BIC is an innovator-centric incubator built on BeiGene’s goal of supporting exploration of new paths to meet patient needs around the world.
The BIC is located in the Guangdong-Hong Kong-Macau Greater Bay Area, an emerging global biotechnology hub, and will feature a comprehensive research infrastructure and professional management team.
The incubator will be equipped with state-of-the-art laboratory infrastructure and comprehensive research capabilities that enable scientists and entrepreneurs to get their ideas off the ground. In addition, scientists and entrepreneurs at the BIC will have potential access to support from BeiGene on full industry value chain integration.
The comprehensive, advanced technology platform at the BIC will allow innovators more autonomy in development, and integrated services to position them for growth.